A new Phase I clinical trial published in a major scientific journal highlights the potential of personalized mRNA vaccines to target glioblastoma, an aggressive brain cancer.
Clinical Trial Insights
Researchers formulated personalized vaccines targeting tumor-specific antigens, triggering a robust T-cell response in patients with newly diagnosed glioblastoma.